Literature DB >> 6479468

The Moro reaction: a scoring system for neonatal narcotic withdrawal.

I J Chasnoff, W J Burns.   

Abstract

A Moro Scale was developed to evaluate the immediate and prolonged effects of neonatal addiction in two matched groups of infants, one delivered to women on low-dose methadone maintenance, the other delivered to drug-free mothers. The Moro reaction was elicited five times in succession in each infant and the most complete reaction was scored on a 20-point scale. There were significant differences between the two groups in mean Moro scores at all ages, and in the duration of the Moro reaction. Significant relationships also were found between total Moro scores and certain items on the Brazelton Scale. The Moro Scale score provides a method of following addicted newborns through the process of withdrawal, and of evaluating CNS irritability and possible early cerebral damage.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6479468     DOI: 10.1111/j.1469-8749.1984.tb04475.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  4 in total

1.  Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting.

Authors:  C H Backes; C R Backes; D Gardner; C A Nankervis; P J Giannone; L Cordero
Journal:  J Perinatol       Date:  2011-08-18       Impact factor: 2.521

2.  Impact of a Standardized Treatment Guideline for Pediatric Iatrogenic Opioid Dependence: A Quality Improvement Initiative.

Authors:  Rima Abdouni; Teri Reyburn-Orne; Tarek H Youssef; Imad Y Haddad; Richard D Gerkin
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

3.  The grasp reflex and moro reflex in infants: hierarchy of primitive reflex responses.

Authors:  Yasuyuki Futagi; Yasuhisa Toribe; Yasuhiro Suzuki
Journal:  Int J Pediatr       Date:  2012-06-11

4.  Neurobehavior of newborn infants exposed prenatally to methadone and identification of a neurobehavioral profile linked to poorer neurodevelopmental outcomes at age 24 months.

Authors:  Trecia A Wouldes; Lianne J Woodward
Journal:  PLoS One       Date:  2020-10-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.